SG11201909016TA - Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety - Google Patents
Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safetyInfo
- Publication number
- SG11201909016TA SG11201909016TA SG11201909016TA SG11201909016TA SG 11201909016T A SG11201909016T A SG 11201909016TA SG 11201909016T A SG11201909016T A SG 11201909016TA SG 11201909016T A SG11201909016T A SG 11201909016TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- california
- tiger
- carlsbad
- suite
- Prior art date
Links
- 230000000845 anti-microbial effect Effects 0.000 title abstract 6
- 125000002091 cationic group Chemical group 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000004599 antimicrobial Substances 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 239000008365 aqueous carrier Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
- 230000036074 healthy skin Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Materials Engineering (AREA)
- Surgery (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482630P | 2017-04-06 | 2017-04-06 | |
| PCT/US2018/026322 WO2018187617A1 (en) | 2017-04-06 | 2018-04-05 | Compositions and uses of locally applied antimicrobials with enhanced performance and safety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909016TA true SG11201909016TA (en) | 2019-10-30 |
Family
ID=63712780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909016T SG11201909016TA (en) | 2017-04-06 | 2018-04-05 | Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11285189B2 (https=) |
| EP (1) | EP3606543A4 (https=) |
| JP (3) | JP2020513016A (https=) |
| KR (2) | KR20240135875A (https=) |
| CN (1) | CN110740744A (https=) |
| AU (2) | AU2018249552A1 (https=) |
| BR (1) | BR112019020781A2 (https=) |
| CA (1) | CA3058901C (https=) |
| MX (2) | MX393548B (https=) |
| SG (1) | SG11201909016TA (https=) |
| WO (1) | WO2018187617A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102266659B1 (ko) | 2012-03-23 | 2021-06-17 | 아미크로베, 인코포레이티드. | 조직-적합성 특성을 갖는 항균물질의 조성물 및 용도 |
| CA3058901C (en) | 2017-04-06 | 2025-05-06 | Amicrobe, Inc. | Compositions and uses of topically applied antimicrobial agents offering improvements in performance and safety |
| JP2023501385A (ja) * | 2019-11-08 | 2023-01-18 | ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 抗微生物ペプチドを含む組成物 |
| CN115397454A (zh) * | 2020-03-31 | 2022-11-25 | 立美基股份有限公司 | 通过辐照对自组装肽进行灭菌 |
| KR20220166832A (ko) * | 2020-04-08 | 2022-12-19 | 아미크로베, 인코포레이티드. | 바이러스 감염의 예방 및 치료를 위한 국소 적용 합성 아미노산 중합체의 조성물 및 용도 |
| US12371463B2 (en) | 2021-04-20 | 2025-07-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods and compositions for treatment of antibiotic-resistant bacterial infections |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5636643A (en) | 1991-11-14 | 1997-06-10 | Wake Forest University | Wound treatment employing reduced pressure |
| US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6680365B1 (en) | 1998-03-19 | 2004-01-20 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| TW570805B (en) | 1998-09-01 | 2004-01-11 | Hoffmann La Roche | Water-soluble pharmaceutical composition in an ionic complex |
| EP1156781B1 (en) | 1999-02-26 | 2005-06-08 | Chiron Corporation | Microemulsions with adsorbed macromolecules and microparticles |
| ES2260291T3 (es) | 2000-09-28 | 2006-11-01 | Chiron Corporation | Microparticulas para la administracion de acidos nucleicos heterologos. |
| US6835536B2 (en) | 2001-08-21 | 2004-12-28 | Micrologix Biotech Inc. | Antimicrobial cationic peptides and formulations thereof |
| WO2003020797A1 (en) | 2001-08-30 | 2003-03-13 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
| JP2003171463A (ja) | 2001-12-06 | 2003-06-20 | Chisso Corp | ポリリジン及びその製造法 |
| CA2443472A1 (en) | 2002-02-07 | 2003-08-14 | Ophtecs Corporation | Liquid formulation for contact lenses |
| CA2509365C (en) | 2002-12-09 | 2012-08-07 | American Bioscience, Inc. | Compositions and methods of delivery of pharmacological agents |
| DE602004012269T2 (de) | 2003-07-11 | 2009-04-30 | Theravance, Inc., South San Francisco | Quervernetzte glycopeptid-cephalosporin-antibiotika |
| WO2005018701A1 (en) | 2003-08-25 | 2005-03-03 | Kane Biotech Inc. | Synergistic antimicrobial compositions and methods of inhibiting biofilm formation |
| WO2005063278A1 (en) | 2003-12-30 | 2005-07-14 | Bioactive Polymers Ab | Surface protection of exposed biological tissues |
| US20080145383A1 (en) | 2004-03-12 | 2008-06-19 | Intercell Ag | Method for Solubilizing Peptide Mixtures |
| EP1927597B1 (en) | 2004-08-18 | 2016-11-02 | Novabiotics Limited | Antibacterial peptides |
| CA2607841C (en) | 2005-06-06 | 2015-11-24 | Novozymes A/S | Polypeptides having antimicrobial activity and polynucleotides encoding same |
| US20080139450A1 (en) | 2005-07-01 | 2008-06-12 | Srinivasa Madhyastha | Antimicrobial Compositions and Uses Thereof |
| US20070190110A1 (en) | 2006-02-10 | 2007-08-16 | Pameijer Cornelis H | Agents and devices for providing blood clotting functions to wounds |
| CA2671461C (en) | 2006-12-01 | 2014-01-28 | The Regents Of The University Of California | Vesicles of self-assembling block copolymers and methods for making and using the same |
| CA2691645A1 (en) | 2007-06-25 | 2008-12-31 | Lipopeptide Ab | New medical products |
| EP2192923A2 (en) | 2007-08-27 | 2010-06-09 | Massachusetts Institute of Technology | Bi-functional polymer-attached inhibitors of influenza virus |
| CA2727428A1 (en) | 2008-06-19 | 2009-12-23 | Nippon Shinyaku Co., Ltd. | Drug carrier |
| CN102256613B (zh) | 2008-10-20 | 2014-09-10 | 莫伊莱麦屈克斯公司 | 用于治疗或者预防粘连的多肽 |
| WO2010083589A1 (en) | 2009-01-23 | 2010-07-29 | Kane Biotech Inc. | Biofilm-removing antimicrobial compositions and uses thereof |
| GB0905451D0 (en) | 2009-03-31 | 2009-05-13 | Novabiotics Ltd | Biofilms |
| EA037276B1 (ru) | 2010-04-27 | 2021-03-03 | Лисандо Аг | Способы устранения или уменьшения бактериальной биопленки |
| JP5902171B2 (ja) | 2010-08-23 | 2016-04-13 | ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | 高抗微生物活性および低毒性を有する材料の組成物および使用 |
| JP5613779B2 (ja) | 2011-01-19 | 2014-10-29 | 株式会社メニコン | コンタクトレンズ用液剤 |
| US9781949B2 (en) | 2011-03-31 | 2017-10-10 | The University Of Massachusetts | Antimicrobial delivery systems, methods of manufacture, and methods of use thereof |
| KR102266659B1 (ko) | 2012-03-23 | 2021-06-17 | 아미크로베, 인코포레이티드. | 조직-적합성 특성을 갖는 항균물질의 조성물 및 용도 |
| DE102014101663A1 (de) | 2014-02-11 | 2015-08-13 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Synthetische artifizielle Peptide mit antimikrobieller Wirkung |
| US10351599B2 (en) | 2014-09-19 | 2019-07-16 | Tensive Controls, Inc. | Anti-microbial peptides |
| AU2015338969B2 (en) * | 2014-10-30 | 2020-08-27 | Biomet Manufacturing, Llc | Methods of preventing surgical site infections |
| JP2016113373A (ja) * | 2014-12-11 | 2016-06-23 | エスポ化学株式会社 | 抗菌性、抗ウイルス性を有する水溶性組成物 |
| CA3058901C (en) | 2017-04-06 | 2025-05-06 | Amicrobe, Inc. | Compositions and uses of topically applied antimicrobial agents offering improvements in performance and safety |
| WO2019169324A1 (en) | 2018-03-02 | 2019-09-06 | January Therapeutics, Inc. | Nanoparticle compositions |
-
2018
- 2018-04-05 CA CA3058901A patent/CA3058901C/en active Active
- 2018-04-05 BR BR112019020781A patent/BR112019020781A2/pt unknown
- 2018-04-05 KR KR1020247029282A patent/KR20240135875A/ko not_active Ceased
- 2018-04-05 EP EP18780547.8A patent/EP3606543A4/en active Pending
- 2018-04-05 AU AU2018249552A patent/AU2018249552A1/en not_active Abandoned
- 2018-04-05 CN CN201880037998.9A patent/CN110740744A/zh active Pending
- 2018-04-05 WO PCT/US2018/026322 patent/WO2018187617A1/en not_active Ceased
- 2018-04-05 MX MX2019011912A patent/MX393548B/es unknown
- 2018-04-05 JP JP2019554855A patent/JP2020513016A/ja active Pending
- 2018-04-05 US US16/500,288 patent/US11285189B2/en active Active
- 2018-04-05 SG SG11201909016T patent/SG11201909016TA/en unknown
- 2018-04-05 KR KR1020197032623A patent/KR20200018400A/ko not_active Ceased
-
2019
- 2019-10-03 MX MX2022007904A patent/MX2022007904A/es unknown
-
2022
- 2022-03-08 US US17/654,021 patent/US12268722B2/en active Active
-
2023
- 2023-02-27 JP JP2023028902A patent/JP7656643B2/ja active Active
- 2023-04-13 AU AU2023202283A patent/AU2023202283A1/en active Pending
-
2025
- 2025-03-24 JP JP2025049135A patent/JP2025090864A/ja active Pending
- 2025-03-25 US US19/090,034 patent/US20260041728A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210100867A1 (en) | 2021-04-08 |
| BR112019020781A2 (pt) | 2020-04-28 |
| RU2019133628A (ru) | 2021-05-06 |
| US20260041728A1 (en) | 2026-02-12 |
| CA3058901A1 (en) | 2018-10-11 |
| MX393548B (es) | 2025-03-24 |
| JP2025090864A (ja) | 2025-06-17 |
| CN110740744A (zh) | 2020-01-31 |
| EP3606543A4 (en) | 2020-12-16 |
| CA3058901C (en) | 2025-05-06 |
| JP7656643B2 (ja) | 2025-04-03 |
| AU2018249552A1 (en) | 2019-10-31 |
| EP3606543A1 (en) | 2020-02-12 |
| US12268722B2 (en) | 2025-04-08 |
| RU2019133628A3 (https=) | 2021-07-14 |
| MX2022007904A (es) | 2022-07-21 |
| JP2023054375A (ja) | 2023-04-13 |
| AU2023202283A1 (en) | 2023-05-11 |
| US11285189B2 (en) | 2022-03-29 |
| WO2018187617A1 (en) | 2018-10-11 |
| WO2018187617A8 (en) | 2019-10-17 |
| US20230017994A1 (en) | 2023-01-19 |
| KR20240135875A (ko) | 2024-09-12 |
| KR20200018400A (ko) | 2020-02-19 |
| JP2020513016A (ja) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909016TA (en) | Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
| SG11201908560SA (en) | Heterocyclic compounds useful as dual atx/ca inhibitors | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201900596XA (en) | Cannabis composition | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201908547VA (en) | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201907742YA (en) | Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201811490XA (en) | Cd3 binding antibodies | |
| SG11201408173WA (en) | Pyrimidinyl tyrosine kinase inhibitors | |
| SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
| CA3025288C (en) | Reduced misting alkaline and neutral cleaning, sanitizing, and disinfecting compositions via the use of high molecular weight water-in-oil emulsion polymers | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201901576QA (en) | Dosage regimen for a controlled-release pth compound | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same |